Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | +0.45% | +7.77% | +16.58% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.35 times its sales, is clearly overvalued in comparison with peers.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.58% | 551M | - | ||
-4.44% | 463B | B- | ||
+14.52% | 126B | A- | ||
-21.15% | 43.5B | A- | ||
-6.08% | 37.2B | B- | ||
-15.17% | 17.96B | B- | ||
-26.20% | 2.61B | C+ | ||
-3.95% | 1.58B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLOV Stock
- Ratings Clover Health Investments, Corp.